MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Topic
Complement system in diseases
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

1,025 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
1,025 works in the cohort · of 4,299,418page 8 of 21

Labels cover 2 of 1,025 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 1,025 of 1,025 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

afffundunlabeled
Characterization of CD200 Ectodomain Shedding
Karrie Wong, Fang Zhu, Ismat Khatri, Qiang Huo, David Spaner, Reginald M. Gorczynski
2016· article· en· PLoS ONE· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
25
citations
affunlabeled
VALIANT: A Randomized, Multicenter, Double-Blind, Placebo (PBO)-Controlled, Phase 3 Trial of Pegcetacoplan for Patients with Native or Post-transplant Recurrent Glomerulopathy (C3G) or Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Carla Nester, Andrew S. Bomback, María Gema Ariceta Iraola, Yahsou Delmas, Bradley P. Dixon, Daniel P. Gale +19 more
2024· article· en· Journal of the American Society of Nephrology· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
24
citations
afffundunlabeled
Malaria Biomimetic for Tumor Targeted Drug Delivery
Jessica Pihl, Thomas Mandel Clausen, Jiarong Zhou, Nishta Krishnan, Maj Sofie Ørum-Madsen, Tobias Gustavsson +8 more
2023· article· en· ACS Nano· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
22
citations
affno abstractunlabeled
Systematic review of atypical hemolytic uremic syndrome biomarkers
Rupesh Raina, Sidharth Kumar Sethi, Marie‐Agnès Dragon‐Durey, Amrit Khooblall, Divya Sharma, Priyanka Khandelwal +5 more
2022· review· en· Pediatric Nephrology· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
21
citations
fundno affunlabeled
Complement and the hallmarks of cancer
Mikel Rezola Artero, Andrea Minery, Leon Nedelcev, Maria Radanova, Lubka T. Roumenina
2025· review· en· Seminars in Immunology· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
19
citations

How this was built: Screen · Findings · About